Understanding how HIV antibodies develop to create better vaccines
The evolutionary landscape of HIV broadly neutralizing antibody development
This study is looking at how certain antibodies that can fight off many types of HIV develop, which could help scientists create a better vaccine for people at risk of HIV.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Utah NIH-funded |
| Lab location | 1 site (Salt Lake City, United States) |
| Project ID | NIH-10913611 on NIH RePORTER |
What this research studies
This research investigates the development of broadly neutralizing antibodies (bnAbs) against HIV, which are crucial for creating an effective vaccine. By analyzing how these antibodies evolve and interact with different strains of the virus, the research aims to identify key features that can enhance vaccine design. The study employs innovative high-throughput biochemical techniques to explore the molecular mechanisms behind antibody function and specificity. Patients may benefit from this research as it could lead to more effective preventive measures against HIV.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals at risk of HIV infection or those living with HIV who may benefit from improved vaccine strategies.
Not a fit: Patients who are already HIV-positive and have access to effective treatment may not directly benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to the development of a more effective HIV vaccine that provides broader protection against various strains of the virus.
How similar studies have performed: Previous research has shown promise in understanding antibody development against HIV, but this approach aims to provide novel insights into the evolutionary mechanisms involved.
Where this research is happening
Salt Lake City, United States
- University of Utah — Salt Lake City, United States (Active)
Researchers
- Principal investigator: Starr, Tyler Nelson — University of Utah
- Study coordinator: Starr, Tyler Nelson
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.